Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacyKristie A. Blum, Ahmed Younes, Daniel L. Combs et al.|Journal of Clinical Oncology|2009Cited by 31
Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell LymphomaAnas Younes, Jeffrey D. Bloss, Jonathan Zalevsky et al.|Blood|2008Cited by 9